Table 1.
Clinical characteristics of the cohort by HPV status and ECE and/or PSM.
| HPV– Negative ECE/PSM (N = 1030) No (%) |
HPV– Positive ECE/PSM (N = 699) No (%) |
P-value | HPV+ Negative ECE/PSM (N = 1749) No (%) |
HPV+ Positive ECE/PSM (N = 1587) No (%) |
P-value | |
|---|---|---|---|---|---|---|
| Sex | <0.01 | <0.01 | ||||
| Male | 737 (71.5) | 537 (76.8) | 1441 (82.4) | 1362 (85.8) | ||
| Female | 293 (28.5) | 162 (23.2) | 308 (17.6) | 225 (14.2) | ||
| Age | <0.01 | <0.01 | 0.76 | |||
| <70 years | 823 (79.9) | 595 (85.1) | 1563 (89.4) | 1413 (89.0) | ||
| ≥70 years | 207 (20.1) | 104 (14.9) | 186 (10.6) | 174 (11.0) | ||
| Race | 0.04 | 0.70 | ||||
| White | 875 (85.0) | 601 (86.0) | 1617 (92.5) | 1475 (92.9) | ||
| Black | 90 (8.7) | 41 (5.9) | 50 (2.9) | 47 (3.0) | ||
| Other | 65 (6.3) | 57 (8.1) | 82 (4.7) | 65 (4.1) | ||
| Insurance | 0.34 | 0.38 | ||||
| Private | 514 (49.9) | 382 (54.7) | 1188 (67.9) | 1032 (65.0) | ||
| Medicare | 357 (34.7) | 228 (32.6) | 392 (22.4) | 388 (24.5) | ||
| Medicaid | 90 (8.7) | 52 (7.4) | 81 (4.6) | 89 (5.6) | ||
| Government/Other | 32 (3.1) | 17 (2.4) | 45 (2.6) | 42 (2.7) | ||
| Uninsured | 37 (3.6) | 20 (2.9) | 43 (2.5) | 36 (2.3) | ||
| Zip code Income | 0.26 | 0.03 | ||||
| ≤38,000 | 181 (17.6) | 111 (15.9) | 184 (10.5) | 180 (11.3) | ||
| 38–48 K | 233 (22.6) | 138 (19.7) | 331 (18.9) | 350 (22.1) | ||
| 48 K-63 K | 269 (26.1) | 200 (28.6) | 471 (26.9) | 445 (28.0) | ||
| ≥63 K | 340 (33.0) | 248 (35.5) | 758 (43.3) | 608 (38.3) | ||
| Urban | 0.18 | 0.17 | ||||
| Lives in Metro | 882 (79.8) | 567 (81.1) | 1419 (81.1) | 1275 (80.3) | ||
| Near Metro | 123 (11.9) | 63 (9.0) | 193 (11.0) | 171 (10.8) | ||
| Far from Metro | 61 (5.9) | 52 (7.4) | 97 (5.6) | 114 (7.2) | ||
| Geography | 0.55 | <0.01 | ||||
| East | 226 (21.9) | 149 (21.3) | 438 (25.0) | 296 (18.7) | ||
| Midwest | 296 (28.7) | 215 (30.8) | 500 (28.6) | 555 (35.0) | ||
| South | 319 (31.0) | 194 (27.8) | 416 (23.8) | 395 (24.9) | ||
| West | 168 (16.3) | 123 (17.6) | 365 (20.9) | 320 (20.2) | ||
| Facility Type | 0.19 | 0.00 | ||||
| Non-Academic | 364 (35.3) | 273 (39.1) | 527 (30.1) | 586 (36.9) | ||
| Academic | 645 (62.6) | 408 (58.4) | 1192 (68.2) | 980 (61.8) | ||
| Charlson-Deyo Score | 0.41 | 0.41 | ||||
| 0 | 784 (76.1) | 544 (77.8) | 1443 (82.5) | 1292 (81.4) | ||
| ≥1 | 246 (23.9) | 155 (22.2) | 306 (17.5) | 295 (18.6) | ||
| Tumor Differentiation | <0.01 | <0.01 | ||||
| Well | 82 (8.0) | 30 (4.3) | 47 (2.7) | 16 (1.0) | ||
| Moderate | 496 (48.2) | 306 (43.8) | 561 (32.1) | 483 (30.4) | ||
| Poor | 349 (33.9) | 292 (41.8) | 899 (51.4) | 838 (52.8) | ||
| Undifferentiated | 7 (0.7) | 9 (1.3) | 25 (1.4) | 43 (2.7) | ||
| Clinical T Stage | <0.01 | 0.01 | ||||
| T1 | 384 (37.3) | 201 (28.8) | 717 (41.0) | 576 (36.3) | ||
| T2 | 395 (38.4) | 267 (38.2) | 639 (36.5) | 589 (37.1) | ||
| T3 | 95 (9.2) | 67 (9.6) | 86 (4.9) | 103 (6.5) | ||
| T4 | 64 (6.2) | 70 (10.0) | 38 (2.2) | 51 (3.2) | ||
| T0/TX | 92 (8.9) | 70 (13.5) | 269 (15.4) | 268 (16.9) | ||
| Clinical N Stage | <0.01 | <0.01 | ||||
| N0 | 513 (49.8) | 131 (18.7) | 468 (26.7) | 136 (8.6) | ||
| N1 | 200 (19.4) | 182 (26.0) | 1224 (70.0) | 1290 (81.3) | ||
| N2 | 300 (29.1) | 329 (47.1) | 39 (2.2) | 90 (5.7) | ||
| N3 | 16 (1.7) | 57 (8.2) | 18 (1.0) | 71 (4.5) | ||
| Treatment Modality | <0.01 | <0.01 | ||||
| Surgery alone | 502 (48.7) | 135 (19.3) | 652 (37.3) | 222 (14.0) | ||
| Surgery + RT | 303 (29.4) | 134 (19.2) | 716 (40.9) | 343 (21.6) | ||
| Surgery + Chemo | 9 (0.9) | 15 (2.2) | 9 (0.5) | 22 (1.4) | ||
| Surgery + CRT | 216 (21.0) | 415 (59.4) | 372 (21.3) | 1000 (63.0) | ||